The global liquid biopsy products market size accounted for USD 5.14 billion in 2024 and is predicted to touch around USD 16.7 billion by 2034, growing at a CAGR of 12.5% from 2025 to 2034. Driven by critical product segments and diverse end-use applications. The liquid biopsy products market is undergoing rapid growth, attributed to increasing cancer incidences and the rising demand for non-invasive diagnostic options.
The market continues to see a strong uptake of multiplexed liquid biopsy tests utilizing next-generation sequencing techniques augmented by artificial intelligence, allowing for earlier and robust multi-biomarker detection for optimal clinical outcomes on a worldwide basis. While the growing incidence of cancer, developing personalized medicine practices, increasing reliance from pharmaceuticals on companion diagnostics, and an increasing awareness of oncological early detection is helping drive global demand for liquid biopsy products, some barriers remain towards broader adoption; their high cost, limited reimbursement landscape, regulatory hurdles, and differences in advanced diagnostic infrastructure remains a limitation for widespread adoption especially in emerging markets and rural health systems. Opportunities remain to broaden clinical applications for prenatal testing, transplant monitoring for solid organ rejection, minimal residual disease detection, and advances utilizing AI to build advanced profiles of circulating tumour DNA and exosomes to improve clinical specificity on a global basis.
In May 2025 announcement from the NHS in England, made for the introduction of liquid biopsy blood tests for breast cancer and lung cancer patients, which should see a quicker result delivery time of 16 days, which in terms of a funding saving of £11 million yearly for screening an estimated 20,000 patients.
